T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment

Carla Casulo, Owen O’Connor, Andrei Shustov, Michelle Fanale, Jonathan W. Friedberg, John P. Leonard, Brad S. Kahl, Richard F. Little, Lauren Pinter-Brown, Ranjani Advani, Steven Horwitz

Affiliations of authors: Wilmot Cancer Center, University of Rochester, Rochester, NY (CC, JWF); Columbia University Medical Center, New York, NY (OO); Seattle Cancer Care Alliance, Seattle, WA (AS); University of Texas MD Anderson Cancer Center, Houston, TX (MF); Department of Medicine, Weil Cornell University, New York, NY (JPL); Oncology Division, Washington University, St. Louis, MO (BSK); Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (RFL); University of California-Irvine Chao Family Comprehensive Cancer Center in Orange, CA (LPB); Stanford Cancer Institute, Stanford University, Stanford, CA (RA); Memorial Sloan-Kettering Cancer Center, New York, NY (SH).

Correspondence to: Carla Casulo, MD, Lymphoma Program, Wilmot Cancer Institute, University of Rochester, 601 Elmwood Avenue, Box 704, Rochester, NY 14642 (e-mail: carla_casulo@urmc.rochester.edu).

Abstract
Peripheral T-cell lymphomas (PTCLs) are uncommon, heterogeneous, and aggressive non-Hodgkin’s lymphomas. Despite progress in the last several years resulting in a deeper understanding of PTCL biology and pathogenesis, there is currently no accepted single standard of care for newly diagnosed patients, and for those with relapsed or refractory disease, prognosis is dismal. The National Cancer Institute convened a Clinical Trials Planning Meeting to advance the national clinical trial agenda in lymphoma. The objective was to identify unmet needs specific to five major lymphoma subtypes and develop strategies to address them. This consensus statement reviews recent advances in the molecular and genetic characterization of PTCL that may inform novel treatments, proposes strategies to test novel therapies in the relapsed setting with the hopes of rapid advancement into frontline trials, and underscores the need for the identification and development of active and biologically rational therapies to cure PTCL at higher rates, with iterative biomarker evaluation.

Recent Advances in Disease Characterization and Management

Epidemiology and Burden of Disease on Population
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous, uncommon, and often aggressive group of non-Hodgkin’s lymphomas (NHL) representing approximately 10% to 15% of all new NHL diagnoses (1). The most recent iteration of the World Health Organization (WHO) classification describes over 20 distinct subtypes of PTCL (2). However, most incident cases are represented by the four most common subtypes: PTCL not otherwise specified (NOS), 34%; angioimmunoblastic T-cell lymphoma (AITL), 14%; anaplastic large cell lymphoma, anaplastic lymphoma kinase-negative (ALK- ALCL), 15%; and anaplastic large cell lymphoma, ALK+ (ALK+ ALCL), 9% (3,4). Compared with B cell NHL, PTCLs carry inferior outcomes. Despite generally favorable response rates to chemotherapy, remissions are often not durable, and as such the natural history of PTCL is characterized by relapses and, in some cases, refractory disease. For that reason, upfront hematopoietic stem cell transplantation (HSCT) is often offered in first remission for patients who are fit and have chemosensitive disease. While phase II studies suggest a benefit of this approach, it is unclear whether the superior outcomes after HSCT are due to patient selection as opposed to a true benefit of HSCT (5,6). Unfortunately, many patients are either not candidates for transplantation or, conversely, are unable to attain a response adequate enough to proceed to transplantation at the time of relapse. For these patients, hopes of long-term disease control are very limited.
Despite progress in the last several years resulting in a deeper understanding of PTCL, at present there is no accepted single standard of care for newly diagnosed patients. The most commonly used regimens have been derived from treatment of aggressive B-cell NHL, such as cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP); cyclophosphamide, doxorubicin, vincristine, etoposide, prednisone (CHOEP); or infusional etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH). Each appears to provide a similar overall response rate (ORR) of approximately 70% to 80%, with a complete response (CR) rate of between 30% and 50% (5,6,8,9), and a five-year overall survival (OS) rate between 25% and 70%. When evaluated based on histology, however, outcomes are poorest for AITL and PTCL-NOS, and slightly better for ALCL (4,8,10–12).

The National Clinical Trials Network (NCTN) has contributed to the treatment landscape of PTCL with several recently completed studies, although, with a few noted exceptions, therapeutic approaches for PTCL have been largely unexplored by the NCTN. The Eastern Cooperative Oncology Group (ECOG) studied the addition of humanized antivascular endothelial growth factor antibody bevacizumab in combination with CHOP in the E2404 study, given a role for angiogenesis in PTCL (13). This phase II study enrolled 46 patients, of whom 39 were evaluable for response. While high overall response rates were observed with bevacizumab-CHOP, the regimen failed to yield durable remissions and was associated with clinically significant and unacceptable grade 3 and 4 toxicities including febrile neutropenia, congestive heart failure, venous thrombosis, and gastrointestinal hemorrhage/perforation. At one year, progression-free survival (PFS) was 44%, with a median OS of 22 months after three years and was associated with clinically significant and unaccept- able grade 3 and 4 toxicities including febrile neutropenia, congestive heart failure, venous thrombosis, and gastrointestinal hemorrhage/perforation. At one year, progression-free survival (PFS) of 5.5 months (7).

In the Southwest Oncology Group O350 study, the PEGS regimen, consisting of cisplatin, etoposide, gemcitabine, and solumedrol, was studied in an attempt to abrogate drug resistance through the selection of drugs not effluxed by the ATP-dependent P-glycoprotein efflux pump (14). In this study, Mahadevan and colleagues reported their experience with 34 patients with PTCL. The combination resulted in a disappointing two-year PFS of 12% (95% confidence interval [CI] = 0.1% to 31%) and a two-year OS of 31% (95% CI = 8% to 54%). Subsequently, many other treatment combinations are being actively explored in PTCL, with the goal of developing biologically based rational therapeutic strategies.

**Areas of Recent Progress in Biological Understanding of Disease**

Recent advances in the molecular and genetic characterization of T-cell lymphomas have helped to delineate differences and similarities between the various subtypes. In the most recent World Health Organization (WHO) Classification of Lymphoid Neoplasms, multiple changes were made to the classification of both nodal and extranodal TCLs. Several recurrent mutations have been identified in small subsets of patients. These genetic alterations are being grouped mechanistically and inform novel treatments. As such, much of the additional genomic information available is being included in the new WHO classification (15).

In PTCL NOS, a targeted deep-sequencing approach in 28 patients revealed epigenetic deregulation as the most frequently mutated category, followed by constitutive T-cell receptor (TCR) activation as the most prominent genetic mechanisms in PTCL pathogenesis (16). Translocation t(5;9)(q33;q32) resulting in the inducible T-cell kinase-spleen tyrosine kinase (ITK-SYK) fusion gene and leading to constitutive activation of the T-cell receptor was found in less than 10% of PTCL NOS (17). Similarly, the recurrent translocation t(6:14) in PTCL juxtaposes the interferon regulatory factor 4 (IRF4) and the TCR alpha genes, resulting in overexpression of IRF4, driving MYC expression and contributing to oncogenesis (18). Expression of the T-cell transcription factor GATA-binding protein 3 (GATA 3) has been found to be elevated in a subset of PTCLs and regulates the production of T helper cells and cytokine production, which are associated with poor outcomes (19). These findings have been recapitulated in genome-wide expression profiling, suggesting the presence of two distinct molecular subgroups of PTCL NOS: one characterized by increased GATA3 expression with poor prognosis and the other by increased expression of t-box 21 (TBX21) transcription factors and corresponding targets (20).

The enzyme isocitrate dehydrogenase 2 (IDH2) is a component of the Krebs cycle that normally catalyzes the conversion of isocitrate to alpha-ketoglutarate, an intermediate for several enzymes involved in epigenetic regulation and adaptation to hypoxia. Neomorphic mutations in IDH2 result in production of 2-hydroxyglutarate, an oncometabolite that represses histone 3 lysine and DNA 5mC demethylation. In AITL, this represents the third most common genetic lesion identified, after the Tet methylation and inactivating DNA (cytosine-5)-methyltransferase 3 alpha (DNMT3A) mutations are seen in many cases of AITL, often in association with the TET2 mutations (23,24). Similarly, regulators of histone methylation were mutated in 25% of AITL cases, including mixed lineage leukemia/lymphoma (MLL2), lysine demethylase 6a (KDM6A), and MLL (20). To date, the presence or absence of these mutations suggests that TET2 mutations may be associated with poor prognosis (24); however, the mutations in epigenetic regulatory genes appear to be particularly frequent in AITL. This supports a potential role for targeting the epigenome in T-cell lymphomas (20,21,23,25) using DNA methyl-transferase...
inhibitor +/- histone deacetylase (HDAC) inhibitors or IDH2 inhibitors (eg, AG-221, NCT02273739). In ALK+ ALCL, the ALK protein is constitutively expressed after fusion to partner genes through chromosomal translocations, most frequently a (2;5)(p23;q35) translocation fusing the ALK gene with NPM on chromosome 5, although other translocations have been reported (26). The ALK chimeras activate Signal transducer and activator of transcription factor 3 (STAT3), deregulation of which is required for maintenance of the neoplastic phenotype in ALK+ ALCL. A systematic characterization of the genetic alterations driving ALCLs was recently undertaken using sequencing strategies. Activating mutations of Janus kinase 1 ([JAK1]) and STAT3 genes were found in 20% of ALK+ ALCLs, 38% of which displayed double lesions (27). Through next-generation sequencing (NGS), recurrent translocations of t(6;7) were recently identified in ALK-ALCLs, leading to a balanced translocation disrupting the dual-specificity phosphatase 22 (DUSP22) gene on chromosome 6, and joining to the fragile site, aphidicolin sensitive, or fragile site, aphidicolin type (FRA) on chromosome 7. This was associated with upregulation of microRNA 29 (28). DUSP22 is a dual-specificity phosphatase that inhibits T-cell antigen receptor signaling in reactive T-cells through mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinase (ERK2) inactivation. More recently, the presence of DUSP22 rearrangement was shown to be associated with a favorable outcome in ALK- ALCL (29). NGS studies have also identified recurrent mutations in p53 and related genes (p63, cyclin dependent kinase [CDKN2A], WW domain containing oxidoreductase [WWOX], ankryin repeat domain 11 [ANKRD11]) in PTCL. In particular, p63 rearrangements were observed in nearly 6% of patients with PTCL and are associated with inferior survival (30).

Aurora A (AA) is a serine/threonine mitotic kinase implicated in oncogenesis through its role in cell division via regulation of chromatid separation. Overexpression of Aurora A kinase (AAK) has been observed in PTCL and is associated with a poorer prognosis (31). In 100 lymphoma samples across the spectrum of PTCL, AAK expression was highest in PTCL-NOS and ALCL and was detected in 68% of cases, including 100% of PTCL NOS (32). In early studies, Alisertib, an oral, selective, competitive, reversible inhibitor of AAK showed an ORR in four out of eight patients with relapsed PTCL (31). Larger studies have shown the ORR to be 30% (95% CI = 9% to 61%) in a phase II study (33) and 33% in a randomized phase III study when compared against other comparators (pralatrexate, romidepsin, gemcitabine) (34), which is consistent with many other available agents in T-cell lymphoma.

This emerging understanding of mutations, targets, and new drugs provides increased rationale for selecting agents and combinations for investigations into novel treatment of PTCLs based on their mechanisms of action.

**Key Clinical Knowledge Gaps and Unmet Clinical Needs**

PTCL is a rare disease and as such the cumulative incidence of many recently discovered mutations is quite low. Consequently, targeting these infrequent mutations in uncommonly occurring disease subtypes is a daunting task. Rather, an approach that targets overarching mechanisms in pathogenesis such as T-cell receptor signaling, epigenetic deregulation, and pathways such as JAK/STAT, phosphatidylinositol 3 (Pi3) kinase, or mammalian target of rapamycin (mTOR) activation may be a more feasible approach that could also apply to greater numbers of patients with various PTCL subtypes and thus provide broader benefit.

The areas most in need of further development in TCL include the identification and development of active and biologically rational therapies to cure PTCL at high rates. These novel agents and/or strategies would be initiated in the relapsed setting where the overall goals would be to generally improve over-all response rates and durability. These discoveries would then be translated into the upfront setting with an aim toward improving CR rates and, if achieved, translating higher CR rates into improved PFS and OS. We recognize that given the current state of therapies, high cure rates are a longer-term goal and will likely be achieved in a step-wise fashion that will be based on other short- and intermediate-term goals. We aim to identify more active therapies and regimens for patients by developing novel platforms in efficiently conducted, and likely sequential, clinical trials to improve upon and/or replace current standard therapies. We also propose to increase our understanding of TCL with an emphasis on inclusion of correlative science in these clinical trials in order to identify biomarkers of response and resistance and thereby better select therapies for individual patients.

**Current Landscape of Ongoing Clinical Trials**

The key to optimizing therapy for patients with PTCL will involve the incorporation of novel agents into well-designed clinical studies to ultimately provide a precision approach to care. The past several years heralded a shift in PTCL, when after decades without meaningful progress in the treatment of relapsed or refractory disease, four drugs were approved worldwide for the treatment of recurrent PTCL. Antifolate pralatrexate and histone deacetylase inhibitor romidepsin have shown statistically significant efficacy in relapsed and refractory PTCL and were approved by the US Food and Drug Administration (FDA) in 2009 and 2011, respectively. Approval of romidepsin for PTCL was based on a pivotal phase II study of patients with relapsed or refractory PTCL (n = 131) that demonstrated an objective response rate of 25%, including 15% with CR; responses lasted a median of greater than two years. Brentuximab vedotin, a CD30-targeted immunoconjugate, demonstrated a high response rate of 85% in a phase II study of 58 patients with CD30+ ALCL who relapsed after prior therapy. Consequently, brentuximab vedotin was approved by the FDA and the European Medicines Agency in 2011 and 2012, respectively, for recurrent CD30+ ALCL. Most recently, the novel pan-histone deacetylase inhibitor belinostat was approved by the FDA in 2014. Belinostat has demonstrated meaningful efficacy and a favorable toxicity profile in a single-arm phase II trial of 129 patients with relapsed/refractory PTCL, with a response rate consistent with rates of other current agents at 28.5% and median duration of response of 13.6 months (95% CI = 4.5 to 29.4) (35). These conclusive results led to an accelerated approval by the FDA.

Approval of these novel agents has led to attempts to improve upon the frequently used CHOP backbone of treatment for PTCL (Table 1). As new agents have shown activity in the relapsed setting, several large international randomized studies have been recently completed, are ongoing, or have been planned comparing the addition of a new agent to the standard CHOP regimen. These studies include the ACT 1 (alemuzumab + CHOP vs CHOP); NCT00646854; ECHELON 2 (brentuximab vedotin + CHP vs CHOP; NCT01777152); Ro-CHOP (romidepsin + CHOP vs
Median PFS was low, at three months (95% CI = 1.6 to 4.9 months) (38). A phase III study of mogamulizumab vs vorinostat in CTCL is ongoing (NCT01728805).

The immunomodulatory drug lenalidomide was studied in a multicenter phase II study of patients with relapsed and refractory TCL (39). Fifty-four patients received 25 mg of lenalidomide for 21 of 28 days for up to 24 months. While the ORR was similar to those of other agents in relapsed TCL at 22% (12 of 54 patients, 95% CI = 12.0 to 35.6), those withAITL did best, with an ORR of 31% and a CR in 15% of patients. Similarly, a Canadian phase II study tested the efficacy of lenalidomide in 40 patients with untreated and relapsed and refractory PTCL (40). The ORR was 29%, with an 8% CR rate in the entire group, but among those previously treated the median OS was 12 months. Unfortunately, the duration of response was low, at five months. To evaluate the role of lenalidomide doublet and triplet combinations, other studies are ongoing, in combination with romidepsin (NCT01742793) and carfilzomib (NCT02341014).

### Table 1. Current landscape of key ongoing and recently completed phase 3 trials*

<table>
<thead>
<tr>
<th>Clinical study</th>
<th>Setting</th>
<th>Therapies being studied</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACT 1 (NCT00646854)</td>
<td>Newly diagnosed, frontline</td>
<td>Alemtuzumab + CHOP vs CHOP (CHOP given every 2 wks)</td>
<td>Primary end point: event-free survival; recruitment complete</td>
</tr>
<tr>
<td>ECHELON 2 (NCT01777152)</td>
<td>Newly diagnosed, frontline</td>
<td>Brentuximab + CHOP vs CHOP</td>
<td>Primary end point: progression-free survival; recruitment ongoing</td>
</tr>
<tr>
<td>Ro-CHOP (NCT01796002)</td>
<td>Newly diagnosed, frontline</td>
<td>Romidepsin + CHOP vs CHOP</td>
<td>Primary end point: progression-free survival; recruitment ongoing</td>
</tr>
<tr>
<td>Lumiere (NCT01482962)</td>
<td>Relapsed and refractory</td>
<td>Alisertib vs pralatrexate vs romidepsin vs gemcitabine</td>
<td>Overall response rate: alisertib 33%, pralatrexate 40% (95% CI = 0.34 to 1.23); pralatrexate 40%; romidepsin 59%; gemcitabine 35%; median PFS in months: 3.7, 3.4, 8, and 1.9, respectively</td>
</tr>
</tbody>
</table>

*CHOP = cyclophosphamide, doxorubicin, oncovin, and prednisone; CI = confidence interval; NCT = National Clinical Trial; PFS = progression-free survival; Ro = romidepsin.

CHOP, NCT01796002), and a planned study of Belinostat + CHOP vs Pralatrexate + CHOP vs CHOP.

Other strategies include the use of HSCT as a common consolidation strategy in the frontline setting for TCL. Prospective phase II studies and retrospective series have shown long-term PFS and OS of 41% to 51% and 44% to 48%, respectively, on an intent-to-treat basis, which compares favorably with the historical and prospective data with CHOP or CHOP-like regimens without consolidation (5,6). While many centers in the United States have adopted consolidation of first remission for HSCT, there is no randomized study to confirm a benefit over chemotherapy alone, and there are no ongoing studies evaluating this question.

In the setting of relapsed disease, advances have been made in the therapeutic armamentarium for PTCL. However, the identification of new therapies to date has been largely empiric. Recent efforts at targeted sequencing have identified several recurrent mutations (listed above) that are promising for the development of new therapies for TCL. However, several of these targets are present in only small subsets of patients with PTCL, presenting a major challenge for study accrual.

As there are four FDA-approved agents for relapsed PTCL—belinostat, brentuximab vedotin (ALCL only), pralatrexate, and romidepsin—combining novel agents is a feasible strategy for improving current therapies. With the exception of brentuximab vedotin for ALCL, the ORR in the relapsed or refractory setting is less than 30% and median PFS is less than five months in the pivotal studies of each of the newer agents (36). Often, in phase I or small phase II signal-finding studies, multiple agents are currently under evaluation as single agents or components of combination therapies for PTCL. However, several of these targets are present in only small subsets of patients with PTCL, making a major challenge for study accrual.

Other strategies include the use of HSCT as a common consolidation strategy in the frontline setting for TCL. Prospective phase II studies and retrospective series have shown long-term PFS and OS of 41% to 51% and 44% to 48%, respectively, on an intent-to-treat basis, which compares favorably with the historical and prospective data with CHOP or CHOP-like regimens without consolidation (5,6). While many centers in the United States have adopted consolidation of first remission for HSCT, there is no randomized study to confirm a benefit over chemotherapy alone, and there are no ongoing studies evaluating this question.

In the setting of relapsed disease, advances have been made in the therapeutic armamentarium for PTCL. However, the identification of new therapies to date has been largely empiric. Recent efforts at targeted sequencing have identified several recurrent mutations (listed above) that are promising for the development of new therapies for TCL. However, several of these targets are present in only small subsets of patients with PTCL, presenting a major challenge for study accrual.

As there are four FDA-approved agents for relapsed PTCL—belinostat, brentuximab vedotin (ALCL only), pralatrexate, and romidepsin—combining novel agents is a feasible strategy for improving current therapies. With the exception of brentuximab vedotin for ALCL, the ORR in the relapsed or refractory setting is less than 30% and median PFS is less than five months in the pivotal studies of each of the newer agents (36). Often, in phase I or small phase II signal-finding studies, multiple agents are currently under evaluation as single agents or components of combination therapies for PTCL. These include the FDA-approved agents that are currently being studied as part of novel combinations with each other or with other frequently used agents such as bortezomib, carfilzomib, lenalidomide, alemtuzumab, 5-azacitidine, gemcitabine, bendamustine, and others. Investigational agents such as PI3 kinase inhibitors, alisertib, mogamulizumab, immune checkpoint inhibitors, and others are also being explored alone or in combination.

Mogamulizumab is a humanized IgG1 monoclonal antibody against chemokine receptor 4 (CCR4). Expression of CCR4 in nodal TCL and cutaneous TCL, as well as in patients with adult T-cell lymphoma/leukemia, makes mogamulizumab an appealing targeted agent (37). A multicenter phase II study in patients with relapsed PTCL as well as cutaneous TCL demonstrated a promising ORR of 35% (95% CI = 20% to 53%), with a 14% CR. Median PFS was low, at three months (95% CI = 1.6 to 4.9 months) (38). A phase III study of mogamulizumab vs vorinostat in CTCL is ongoing (NCT01728805).

The immunomodulatory drug lenalidomide was studied in a multicenter phase II study of patients with relapsed and refractory TCL (39). Fifty-four patients received 25 mg of lenalidomide for 21 of 28 days for up to 24 months. While the ORR was similar to those of other agents in relapsed TCL at 22% (12 of 54 patients, 95% CI = 12.0 to 35.6), those withAITL did best, with an ORR of 31% and a CR in 15% of patients. Similarly, a Canadian phase II study tested the efficacy of lenalidomide in 40 patients with untreated and relapsed and refractory PTCL (40). The ORR was 29%, with an 8% CR rate in the entire group, but among those previously treated the median OS was 12 months. Unfortunately, the duration of response was low, at five months. To evaluate the role of lenalidomide doublet and triplet combinations, other studies are ongoing, in combination with romidepsin (NCT01742793) and carfilzomib (NCT02341014).

### Recommended High-Priority Clinical Trial Questions

**Trial Structure Including Current Standards of Care**

The committee believes that, given the current inadequacies in standard therapy for TCL, simultaneous studies should be conducted so patients progressing on one therapy would have immediate access to other novel approaches. This can best be achieved by studying patients with relapsed or refractory disease. A sequential study design could begin with a series of novel mechanisms based combinations with the ultimate aim of developing a regimen to replace CHOP in the upfront setting.

One approach could include a randomized phase II trial to select the most promising combinations with the highest CR or ORR rate. Selection of these combinations should be based on preclinical rationale and preliminary efficacy demonstrated in phase I/II trials and pilot studies of novel doublets or triplets. Moreover, approaches that target mechanisms of pathogenesis may be a useful paradigm that can be applied to various PTCL subtypes to optimize outcome. Novel doublets have recently been studied or are currently being studied in early trials including romidepsin + lenalidomide, which showed a 60% ORR in relapsed PTCL (41). Other combinations being investigated include romidepsin and pralatrexate, being evaluated currently in an ongoing phase I study (NCT01947140). The combination shows efficacy in vitro, suggesting the potential for synergism (42).
Similarly, the combination of alisertib and romidepsin is being evaluated in a phase I study based on preclinical data supporting efficacy of the combination (43). Other possibilities would include targeting epigenetic modifications using a doublet of a histone deacetylase inhibitor and hypomethylating agent, as is already ongoing with 5-azacitidine + romidepsin (NCT01998035). The most promising of these doublets could be compared with select combinations in a subsequent randomized phase II trial. Once a preferred backbone is established, third agents could be added in parallel phase I studies, followed by randomized phase II studies of the new combinations.

End Points for Clinical Trials in PTCL

The preferred end point for considering when to move a regimen to front line is CR, preferably in conjunction with a predictive biomarker (Figure 2). Defining a response rate in the relapsed setting that warrants consideration as a frontline regimen is arbitrary and based on many other factors such as the toxicity of the regimen and durability of responses. However, given that the goal of a frontline therapy is cure, we believe that a CR of greater than 30% in the relapse setting suggests robust enough activity to be considered.

Biomarkers in PTCL

Biomarker discovery should be an important component of the tier 1 studies (Figure 2). This will increase understanding of the mechanisms of response and resistance and support simultaneous tier 2 studies involving targeted agents, to which patients progressing on the tier 1 studies could be assigned on the basis of biological characteristics. Notable biomarkers relevant to TCL are listed in Table 2. While most current treatment choices derive from studies in which patients with a broad spectrum of TCL subtypes were treated nonselectively, two agents with targets that are more clearly defined are the CD30 targeted antibody drug conjugates brentuximab vedotin and crizotinib, an oral small-molecule tyrosine kinase inhibitor of ALK and several other kinases. As understanding of PTCL increases, there is an opportunity to better refine therapeutic decisions for patients and identify new agents. Recent studies with brentuximab vedotin have provided into disease settings other than anaplastic large cell lymphoma in which it may have the greatest activity and which groups of patients are most likely to benefit from these studies. A recent multi-institution collaborative project reported activity of brentuximab across a wide range of CD30 expression levels in mycosis fungoides demonstrated an ORR of 41% (50). New insights into alternative mechanisms of action and predictors of response may allow extension of the use of brentuximab vedotin to a wider population of patients with PTCL.

Targeting ALK

Crizotinib is an example of therapy for PTCL based upon an understood mechanism and defined target. As in PTCL, ALK harbors an activating mutation in lung cancer and crizotinib is now commonly used in the treatment of the 3% to 5% of patients with non–small cell lung cancers with a rearrangement of the ALK gene (48). Although the presence of mutated ALK in ALCL is a favorable prognostic marker, relapses following chemotherapy occur, with poor outcomes (3). A small study of crizotinib in ALCL demonstrated promising response rates, suggesting a role for ALK inhibition in TCL. Several other ALK inhibitors are being actively developed.

Targeting CD30

The antibody drug conjugate brentuximab vedotin is an anti-CD30 monoclonal antibody fused via a protease-cleavable linker to the antitubulin agent monomethyl auristatin E. CD30 is a transmembrane receptor of the tumor necrosis factor (TNF) superfamily that is often expressed by activated lymphocytes and in some lymphoid malignancies, including ALCL, with more variable expression in other T-cell lymphomas. A phase II study of 58 patients with relapsed/refractory systemic ALCL showed a promising 86% ORR (95% CI = 74.6% to 93.9%), with a 57% CR rate (95% CI = 43.2% to 69.8%) (49). A phase II study in PTCLs other than ALCL with any degree of CD30 expression had an ORR of 41% (50). New insights into alternate mechanisms of action and predictors of response may allow extension of the use of brentuximab vedotin to a wider population of patients with PTCL.

Aurora A Kinase Inhibition

Inhibition of aurora A kinase has previously been shown to cause cell cycle arrest and apoptosis in preclinical studies (31). The oral, reversible inhibitor of AAK alisertib has shown promising response rates. A single-arm intergroup phase II study of 37 patients with relapsed and refractory PTCL as well as transformed mycoses fungoides demonstrated an ORR of 30% (95% CI = 9% to 61%) (33). Because of these findings, a randomized phase III clinical trial comparing alisertib with standard options of pralatrexate, romidepsin, or gemcitabine in subjects with relapsed PTCL has recently completed enrollment, with no discernible difference in response rates among the agents (34).

Phosphatidylinositol-3-kinase (PI3K) inhibition

The PI3K family consists of several serine/threonine and lipid kinases. These enzymes and their downstream targets, primarily Akt, play a major role in multiple cellular processes,
including growth, differentiation, metabolism, survival, and cellular proliferation \( (51) \). Aberrant activation of the PI3K/AKT/mTOR pathway in lymphoma results from several alterations, including mutation or gene amplification, leading to increased pathway activity \( (52) \). A subset of patients with PTCL have been treated with the PI3 kinase delta and gamma inhibitor ipi-145 (duvelisib), with an ORR of 42%, including responses in 53% of those with PTCL \( (53) \). Further studies of PI3 kinase inhibition as part of a combinatorial strategy for T-cell lymphoma are in development.
**Targeting FYN Tyrosine Kinase**

The FYN tyrosine kinase is one of the predominant SRC family kinases expressed in T lymphocytes (54) and has an integral role in T-cell activation upon T-cell receptor stimulation. Recently mutations in FYN tyrosine kinase were noted in a small number (3%, 4/137) of TCLs (PTCL NOS and AITL). While the mutation is quite rare, dasatinib, a multikinase inhibitor that blocks ABL1 and SRC kinases, was shown to inhibit the activity of FYN mutant proteins and impair the growth of transformed cells expressing mutated FYN (54). Based on this preclinical data, SRC kinase inhibition with dasatinib may represent a targeted therapy in the rare PTCL cases with activating mutations in the FYN kinase gene.

**JAK/STAT inhibition**

JAK/STAT signaling is aberrantly activated in lymphoma by multiple mechanisms, including inappropriate autocrine and paracrine cytokine stimulation (55) as well as activating mutations (56). Preclinical studies involving the JAK3 inhibitor CP-690550 demonstrated suppression of the dissemination of NK/T-cell tumor cells in the bone marrow, spleen, and blood (57). An oral JAK3 inhibitor, tofacitinib, is currently approved for the treatment of rheumatoid arthritis (58), and trials of other JAK3 inhibitors are in development. Similarly, the oral JAK inhibitor ruxolitinib is being studied in relapsed B-cell NHL and PTCL (NCT01431209).

**Conclusions and Recommendations**

The continuous discovery of mutations, targets, and new drugs provides a rationale for selecting treatments for PTCL based on mechanism of action and tumor biology. CHOP + X approaches are already ongoing, and no other novel regimens have sufficient preliminary data to warrant being studied in untreated patients. A randomized study evaluating the role of ASCT in the first-line setting should be critically assessed, but the committee has concerns about feasibility. Exploratory studies assessing biomarker development and/or MRD as companions to standard of care in the upfront setting are recommended. In the relapsed setting, sequential studies to develop optimal novel combinations (doublets and triplets) with prospective evaluation of biomarkers for discovery and to triage patients for phase I and II studies of targeted agents are recommended.

**Funding**

Partial support was from the Office of the Director, Coordinating Center for Clinical Trials, National Cancer Institute/National Institutes of Health.

**Notes**

The funders had no role in the writing of the review or decision to submit it for publication.

This manuscript resulted from a Clinical Trials Planning Meeting in Lymphoma, November 21–22, 2014.

**References**

lymphoma. Paper presented at the 56th Meeting of the American Society for Hematology, December 2014; San Francisco, CA.


